EC Neurology

Review Article Volume 15 Issue 6 - 2023

You Can’t Buy Happiness, But You Can Have a Healthy Gut: Therapeutic Effects for Depression via the Gut-Brain Axis

Katie Tovar, James F Keane and Leonard B Goldstein*

A.T. Still University, USA

*Corresponding Author: Leonard B Goldstein, Assistant Vice President for Clinical Education Development, ATSU Academic Affairs, A.T. Still University, Mesa, AZ, USA.
Received: March 30, 2023; Published: May 06, 2023

The World Health Organization states that Major Depressive Disorder (MDD) is a leading cause of disability, affecting about 300 million people worldwide, and is expected to be the leading burden of disease by 2030. Pharmacological therapy for depression is only effective for 74% of patients. The ineffectiveness of therapy, in addition to the overprescribing of antidepressants, has pushed research to explore the gut-brain-microbiota axis and evaluate it as a therapeutic option when addressing mental health. We have conducted a review of the PubMed databases focusing on the past decade, with consideration to the physiological make-up of depression, serotonin, gut-brain axis, and the pros and cons associated with them. We also considered the influence of the COVID-19 and its long-term effects associated with depression and gut microbiome. Studies have established how unhealthy microbiota results in lower serotonin levels, which are seen in patients with MDD. Similarly, research has uncovered various bacteria, hormonal influences, target pathways, and lifestyle changes, which have been shown to improve the health of the gut, increase serotonin levels, and provide an overall positive influence on the patient’s wellbeing. Gaining further understanding of the gut’s microbiome and effects of treatment, such as bacteriophage therapy, will help clarify the role of the gut in MDD and allow researchers to optimize the gut’s overall health with the goal of providing a more comprehensive, effective treatment for patients affected by MDD. As research continues and understanding of how the gut communicates with the brain comes to fruition, treatment of MDD will stand a higher chance of yielding healthy guts and happy people.

Keywords: Happiness; Healthy Gut; Depression; Gut-Brain Axis

  1. Winter G., et al. “Gut Microbiome and Depression: What We Know and What We Need to Know”. Review of the Neurosciences6 (2018): 629-643.
  2. Ho P and Ross DA. “More Than a Gut Feeling: The Implications of the Gut Microbiota in Psychiatry”. Biological Psychiatry 5 (2017): e35-e37.
  3. Vlainic JV., et al. “Probiotics as an Adjuvant Therapy in Major Depressive Disorder”. Current Neuropharm8 (2016): 952-958.
  4. Opie RS., et al. “Dietary Recommendations for the Prevention of Depression”. Nutritional Neuroscience 3 (2017): 161-171.
  5. Huang R., et al. “Effect of Probiotics on Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials”. Nutrients8 (2016): 483.
  6. Nadeem I., et al. “Effect of Probiotic Interventions on Depression Symptoms: A Narrative Review evaluating”. Systemic Reviews (2021): 1-9.
  7. Pandya M., et al. “Where in the Brain Is Depression?” Current Psychiatry Reports6 (2012): 634-642.
  8. Martin AM., et al. “The Diverse Metabolic Roles of Peripheral Serotonin”. Endocrinology5 (2017): 1049-1063.
  9. Oluboka OJ., et al. “Functional Recovery in Major Depressive Disorder: Providing Early Optimal Treatment for the Individual Patient”. International Journal of Neuropsychopharmacology2 (2017): 128-144.
  10. Dehhaghi M., et al. “Microorganisms, Tryptophan Metabolism, and Kynurenine Pathway: A Complex Interconnected Loop Influencing Human Health Status”. International Journal of Tryptophan Research 12 (2019): 117864691985299.
  11. Qaseem A., et al. “Nonpharmacologic Versus Pharmacologic Treatment of Adult Patients with Major Depressive Disorder: A Clinical Practice Guideline from the American College of Physicians”. Annals of Internal Medicine5 (2016): 350.
  12. Logan AC and Katzman M. “Major depressive disorder: probiotics may be an adjuvant therapy”. Medical Hypotheses3 (2005): 533-538.
  13. Thompson E. “Gut Feeling, Gut Thinking”. Journal of Young Investigators (2019).
  14. Vlaini JV., et al. “Probiotics as an Adjuvant Therapy in Major Depressive Disorder”. Current Neuropharmacology8 (2016): 952-958.
  15. Marathe SV., et al. “Effects of Monoamines and Antidepressants on Astrocyte Physiology: Implications for Monoamine Hypothesis of Depression”. Journal of Experimental Neuroscience 2 (2018): 117906951878914.
  16. O’Mahony S., et al. “Serotonin, tryptophan metabolism and the brain-gut-microbiome axis”. Behavioural Brain Research 277 (2015): 32-48.
  17. Boku S., et al. “Neural basis of major depressive disorder: Beyond monoamine hypothesis”. Psychiatry and Clinical Neurosciences1 (2017): 3-12.
  18. Yano JM., et al. “Indigenous Bacteria from the Gut Microbiota Regulate Host Serotonin Biosynthesis”. Cell2 (2015): 264-276.
  19. Yoo BB and Mazmanian SK. “The Enteric Network: Interactions between the Immune and Nervous Systems of the Gut”. Immunity6 (2017): 910-926.
  20. Berger M., et al. “The Expanded Biology of Serotonin”. Annual Review of Medicine1 (2009): 355-366.
  21. Msetfi RM., et al. “SSRI enhances sensitivity to background outcomes and modulates response rates: A randomized double blind study of instrumental action and depression”. Neurobiology of Learning and Memory 131 (2016): 76-82.
  22. Jenkins T., et al. “Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis”. Nutrients1 (2016): 56.
  23. The Brain-Gut-Microbiome Axis. Cellular and Molecular Gastroenterology and Hepatology (2019).
  24. Chen G-L and Miller GM. “Tryptophan hydroxylase-2: An emerging therapeutic target for stress disorders”. Biochemical Pharmacology9 (2013): 1227-1233.
  25. Kraus C., et al. “Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression”. Neuroscience and Biobehavioral Reviews 77 (2017): 317-326.
  26. Clarke G., et al. “The microbiome-gut-brain axis during early life regulates the hippocampal serotonergic system in a sex-dependent manner”. Molecular Psychiatry6 (2012): 666-673.
  27. Borrelli L., et al. “Probiotic modulation of the microbiota-gut-brain axis and behaviour in zebrafish”. Scientific Reports1 (2016).
  28. Evrensel A and Ceylan ME. “The Gut-Brain Axis: The Missing Link in Depression”. Clinical Psychopharmacology and Neuroscience3 (2015): 239-244.
  29. Crumeyrolle-Arias M., et al. “Absence of the gut microbiota enhances anxiety-like behavior and neuroendocrine response to acute stress in rats”. Psychoneuroendocrinology 42 (2014): 207-217.
  30. Hoban A., et al. “Behavioural and neurochemical consequences of chronic gut microbiota depletion during adulthood in the rat”. Neuroscience 339 (2016): 463-477.
  31. Kelly JR., et al. “Transferring the blues: Depression-associated gut microbiota induces neurobehavioural changes in the rat”. Journal of Psychiatric Research 82 (2016): 109-118.
  32. Thursby E and Juge N. “Introduction to the human gut microbiota”. Biochemical Journal11 (2017): 1823-1836.
  33. Liang S., et al. “Gut-Brain Psychology: Rethinking Psychology from the Microbiota–Gut–Brain Axis”. Frontiers in Integrative Neuroscience (2018): 12.
  34. Neu J and Rushing J. “Cesarean Versus Vaginal Delivery: Long-term Infant Outcomes and the Hygiene Hypothesis”. Clinics in Perinatology2 (2011): 321-331.
  35. Israelyan N., et al. “Effects of Serotonin and Slow-Release 5-Hydroxytryptophan on Gastrointestinal Motility in a Mouse Model of Depression”. Gastroenterology (2019).
  36. Lukić I., et al. “Role of Tryptophan in Microbiota-Induced Depressive-Like Behavior: Evidence from Tryptophan Depletion Study”. Frontiers in Behavioral Neuroscience (2019): 13.
  37. Prendergast GC., et al. “Discovery of IDO1 Inhibitors: From Bench to Bedside”. Cancer Research (2019).
  38. Francescangeli J., et al. “The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice”. International Journal of Molecular Sciences9 (2019): 2288.
  39. Burchill E., et al. “The Unique Impact of COVID-19 on Human Gut Microbiome Research”. Frontiers in Medicine (2021): 8.
  40. Mazza MG., et al. “Post-COVID-19 Depressive Symptoms: Epidemiology, Pathophysiology, and Pharmacological Treatment”. CNS Drugs7 (2022): 681-702.
  41. Wiley NC., et al. “The microbiota-gut-brain axis as a key regulator of neural function and the stress response: Implications for human and animal health”. Journal of Animal Science7 (2017): 3225.
  42. Tetel MJ., et al. “Steroids, stress and the gut microbiome-brain axis”. Journal of Neuroendocrinology2 (2018): 10.

Leonard B Goldstein., et al. “You Can’t Buy Happiness, But You Can Have a Healthy Gut: Therapeutic Effects for Depression via the Gut-Brain Axis”. EC Neurology  15.6 (2023): 01-11.